[Chemotherapy of MRSA infections].
Inamatsu
T
T
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005578:Fosfomycin / Q000627:therapeutic use; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013420:Sulfamethoxazole / Q000008:administration & dosage; D014295:Trimethoprim / Q000008:administration & dosage; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005578:Fosfomycin; D003982:Dibekacin; D014640:Vancomycin; D015378:Imipenem; D014295:Trimethoprim; C031986:arbekacin; D013420:Sulfamethoxazole